GRA Venture — 2021 Investments

1 investments dated 2021 · listed companies and verified rows first · show all

Antios Therapeuticsantiostherapeutics.com in 𝕏Nov 2021 · $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling Capital Altium Capital Avego BioScience Capital Pontifax Venture Capital Amzak Health Delos Capital +8 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.